Oncobiologics prices IPO at $6, as expected

Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, raised $35 million by offering 5.8 million units at $6.

Oncobiologics plans to list on the Nasdaq under the symbol ONS. Jefferies and Barclays acted as lead managers on the deal.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.